# Paired-Box (PAX) Gene Signatures as a Biomarker of Breast Cancer Progression

## TL;DR

This paper explores how specific PAX genes are linked to breast cancer progression and could serve as biomarkers for predicting metastasis and treatment response.

## Contribution

The study identifies novel PAX gene signatures associated with breast cancer hallmarks and metastasis prediction.

## Key findings

- PAX1 and PAX9 correlate with both cell death and proliferation markers.
- PAX3, PAX5, and PAX8 are linked to immune checkpoint expression like PD-L1 and TIGIT.
- PAX2–PAX7 signatures accurately predict lymph node metastasis at the transcriptomic level.

## Abstract

Breast cancer is the leading cause of cancer-related death in women, and despite advances in preventive screening as well as in molecular classification, many patients still do not benefit from existing therapies, highlighting the importance of identifying new molecular determinants of treatment resistance. The Paired-box (PAX) family of developmental transcription factors are central regulators of tissue morphogenesis and lineage specification, yet their reactivation in tumors and contribution to breast cancer progression remain only partially defined. Here, a multi-level analysis integrating RNA sequencing and protein profiling in twenty-one primary breast carcinomas shows that distinct PAX members are directly correlated to distinct fundamental cancer hallmarks, including proliferation, cell death, epithelial–mesenchymal transition, immune evasion, and genomic instability. Specifically, PAX1 and PAX9 correlates with both cell death and proliferative markers, indicating dual roles in the regulation of cell fate. PAX1 and PAX9 correlate with both proliferative and apoptotic markers, indicating dual roles in cell fate regulation. PAX3, PAX5, and PAX8 are mainly associated with immune checkpoint expression, including PD-L1 and TIGIT, while PAX6 is linked to microsatellite instability and tumor mutational burden, implicating it in genomic dysregulation. Therefore, PAX-based molecular signatures identify that accurately predict lymph node metastasis at transcriptomic (PAX2–PAX7) levels. These findings establish PAX transcription factors as key modulators of breast cancer biology and support their potential as clinically relevant biomarkers for prognostic refinement and therapeutic stratification.